Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis.

Idiopathic pulmonary fibrosis, often called IPF, is a condition that causes progressive scarring in the lungs. Over time, this scarring makes the lungs less flexible, leading to shortness of breath, a persistent dry cough, and tiredness. While existing treatments can help slow down the disease, they cannot cure it or reverse existing scars. Because of this, medical researchers are continually searching for new medicines that can better manage or halt the condition.

This trial focuses on a new drug known as CMR316. Before any new medicine can be used in clinics, it must go through careful testing. This is a Phase 1 clinical study, which represents the very first step of human testing. The main purpose is human pharmacology, which means scientists want to observe how the drug behaves inside the body, how it is broken down, and whether it causes any uncomfortable or harmful side effects.

To build a full safety profile, the researchers are inviting both healthy volunteers and people living with IPF to take part. Testing the medicine in healthy individuals shows how it works under normal conditions, while testing it in people with IPF helps researchers understand how the disease itself might affect how the medicine works.

Although Phase 1 trials are not designed to cure the illness, the knowledge gained from them is essential. Every modern medicine used in the NHS today began with early safety studies like this one. By taking part, participants help provide the fundamental evidence needed to decide if CMR316 should move forward into larger studies.